Skip to main content
PMC home page
Journal of Assisted Reproduction and Genetics logoLink to Journal of Assisted Reproduction and Genetics
editorial
. 2003 Jan;20(1):29–32. doi: 10.1023/A:1021258721796

Confronting the Hidden Face of Progesterone During the Follicular Phase

Dominique de Ziegler 1, Pierre-Alain Brioschi 1, Renato Fanchin 1, Carlo Bulletti 2
PMCID: PMC3455796  PMID: 12645865

Abstract

Sporadic cases of late follicular phase progesterone elevation have been described in ART cycles despite routine blockage of endogenous gonadotropins with GnRH agonists, the mechanism of which has been eluding our scrutiny. In this issue of JARG, Levran et al. report the first cases of adult-onset mild form of congenital adrenal hyperplasia (CAH) linked to a deficit in 17-hydorixyloase (17-OH ase). Contrary to CAH due to deficit 21-OH ase, these not only affect the adrenals but also the FSH driven production of E2 and androgen by the ovary thereby leading to progesterone “accumulation” during the follicular phase. Levran's findings offer new hypotheses for explaining the cases late follicular progesterone elevation particularly, when encountered in COH cycles associated with poor E2 elevation. And more importantly, Levran's findings offer new possible options for minimizing their consequences on ART outcome.

Keywords: Progesterone, CAH, Follicular phase, COH

Full Text

The Full Text of this article is available as a PDF (48.7 KB).

REFERENCES

  • 1.Ferenczy A, Bertrand G, Gelfand MM. Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol. 1979;133:859–867. doi: 10.1016/0002-9378(79)90302-8. [DOI] [PubMed] [Google Scholar]
  • 2.Ayoubi JM, Brioschi PA, Fanchin R, Epiney M, Campana A, de Ziegler D. Comparison of changes in uterine contraction frequency after ovulation in the menstrual cycle and in vitro fertilization cycle. Fertil Steril, in press [DOI] [PubMed]
  • 3.Levran D, Ben-Shlomo I, Pariente C, Dor J, Mashiach S, Weisman A. Famillial partial 17,20 desmolase and 17-hydroxylase deficiency presenting as infertility. J Assit Reprod Genet, in Press [DOI] [PMC free article] [PubMed]
  • 4.Schoolcraft W, Sinton E, Schlenker T, Huynh D, Hamilton F, Meldrum DR. Lower pregnancy rate with premature luteinization during pituitary suppression with leuprolide acetate. Fertil Steril. 1991;55:563–566. [PubMed] [Google Scholar]
  • 5.Mio Y, Sekijima A, Iwabe T, Onohara Y, Harada T, Terakawa N. Subtle rise in serum progesterone during the follicular phase as a predictor of the outcome of in vitro fertilization. Fertil Steril. 1992;58:159–166. doi: 10.1016/s0015-0282(16)55154-1. [DOI] [PubMed] [Google Scholar]
  • 6.Dirnfeld M, Goldman S, Gonen Y, Koifman M, Lissak A, Abramovici H. A modest increase in serum progesterone levels on the day of human chorionic gonadotropin (hCG) administration may influence pregnancy rate and pregnancy loss in in vitro fertilization-embryo transfer (IVF-ET) patients. J Assist Reprod Genet. 1993;10:126–129. doi: 10.1007/BF01207734. [DOI] [PubMed] [Google Scholar]
  • 7.Fanchin R, de Ziegler D, Taieb J, Hazout A, Frydman R. Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transfer. Fertil Steril. 1993;59:1090–1094. doi: 10.1016/s0015-0282(16)55933-0. [DOI] [PubMed] [Google Scholar]
  • 8.Silverberg KM, Burns WN, Olive DL, Riehl RM, Schenken RS. Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins. J Clin Endocrinol Metab. 1991;73:797–803. doi: 10.1210/jcem-73-4-797. [DOI] [PubMed] [Google Scholar]
  • 9.G Givens CR, Schriock ED, Dandekar PV, Martin MC. Elevated serum progesterone levels on the day of human chorionic gonadotropin administration do not predict outcome in assisted reproduction cycles. Fertil Steril. 1994;62:1011–1017. doi: 10.1016/s0015-0282(16)57066-6. [DOI] [PubMed] [Google Scholar]
  • 10.Hofmann GE, Khoury J, Johnson CA, Thie J, Scott RT., Jr. Premature luteinization during controlled ovarian hyperstimulation for in vitro fertilization-embryo transfer has no impact on pregnancy outcome. Fertil Steril. 1996;66:980–986. doi: 10.1016/s0015-0282(16)58693-2. [DOI] [PubMed] [Google Scholar]
  • 11.Abuzeid MI, Sasy MA. Elevated progesterone levels in the late follicular phase do not predict success of in vitro fertilization-embryo transfer. Fertil Steril. 1996;65:981–985. doi: 10.1016/s0015-0282(16)58273-9. [DOI] [PubMed] [Google Scholar]
  • 12.Lindheim SR, Cohen MA, Chang PL, Sauer MV. Serum progesterone before and after human chorionic gonadotropin injection depends on the estradiol response to ovarian hyperstimulation during in vitro fertilization-embryo transfer cycles. J Assist Reprod Genet. 1999;16:242–246. doi: 10.1023/A:1020311328182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Fanchin R, Righini C, Olivennes F, de Ziegler D, Selva J, Frydman R. Premature progesterone elevation does not alter oocyte quality in in vitro fertilization. Fertil Steril. 1996;65:1178–1183. doi: 10.1016/s0015-0282(16)58335-6. [DOI] [PubMed] [Google Scholar]
  • 14.Fanchin R, Righini C, Olivennes F, Ferreira AL, de Ziegler D, Frydman R. Consequences of premature progesterone elevation on the outcome of in vitro fertilization: Insights into a controversy. Fertil Steril. 1997;68:799–805. doi: 10.1016/s0015-0282(97)00337-3. [DOI] [PubMed] [Google Scholar]
  • 15.Adonakis G, Deshpande N, Yates RW, Fleming R. Luteinizing hormone increases estradiol secretion but has no effect on progesterone concentrations in the late follicular phase of in vitro fertilization cycles in women treated with gonadotropin-releasing hormone agonist and follicle-stimulating hormone. Fertil Steril. 1998;69:450–453. doi: 10.1016/s0015-0282(97)00559-1. [DOI] [PubMed] [Google Scholar]
  • 16.Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, de Fatis CT, Pocognoli P. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J Clin Endocrinol Metab. 1999;84:2659–2663. doi: 10.1210/jcem.84.8.5884. [DOI] [PubMed] [Google Scholar]
  • 17.Filicori M, Cognigni GE, Tabarelli C, Pocognoli P, Taraborrelli S, Spettoli D, Ciampaglia W. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab. 2002;87:1156–1161. doi: 10.1210/jcem.87.3.8322. [DOI] [PubMed] [Google Scholar]
  • 18.White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000;21:245–291. doi: 10.1210/edrv.21.3.0398. [DOI] [PubMed] [Google Scholar]
  • 19.Chetkowski RJ, DeFazio J, Shamonki I, Judd HL, Chang RJ. The incidence of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency among hirsute women. J Clin Endocrinol Metab. 1984;58:595–598. doi: 10.1210/jcem-58-4-595. [DOI] [PubMed] [Google Scholar]
  • 20.Fitness J, Dixit N, Webster D, Torresani T, Pergolizzi R, Speiser PW, Day DJ. Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1999;84:960–966. doi: 10.1210/jcem.84.3.5550. [DOI] [PubMed] [Google Scholar]
  • 21.Knochenhauer ES, Cortet-Rudelli C, Cunningham RD, Conway BA, Dewailly D, Azziz R. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. J Clin Endocrinol Metab. 1997;82:479–485. doi: 10.1210/jcem.82.2.3759. [DOI] [PubMed] [Google Scholar]
  • 22.Witchel SF, Lee PA, Suda-Hartman M, Hoffman EP. Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency. Biochem Mol Med. 1997;62:151–158. doi: 10.1006/bmme.1997.2632. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Assisted Reproduction and Genetics are provided here courtesy of Springer Science+Business Media, LLC

RESOURCES